Abstracts tagged "population studies"

Abstract Number: 0148 • ACR Convergence 2024
The Incidence and Prevalence of Sarcoidosis in England
Katie Bechman¹, Kathryn Biddle¹, Mark Russell², Mark Gibson¹, maryam adas¹, Zijing Yang², Edward Alveyn¹, deepak Nagra², Sam Norton², Surinder biring¹ and James Galloway³, ¹King's College London, London, United Kingdom, ²King's College London, London, England, United Kingdom, ³Centre for Rheumatic Diseases, King's College London, London, United Kingdom
Background/Purpose: Sarcoidosis is heterogeneous condition, ranging from mild self-limiting disease to severe organ involvement and death. Despite its clinical significance, the epidemiological landscape in England…
Abstract Number: 2126 • ACR Convergence 2024
Analysis of the Evolution of Bone Mineral Density in the Spanish Population: Results of the OsteoSER Study
Carmen Gomez Vaquero¹, Marta Domínguez-Álvaro², Daniel Seoane-Mato³, Pilar Peris⁴, Santos Castañeda⁵, Eduardo Kanterewicz Binstock⁶, Ramon Mazzucchelli⁷, Luis Arboleya⁸, Miguel Bernad⁹, Antonio Alvarez-Cienfuegos¹⁰, Blanca Correa¹¹, Luis-Maria Jimenez-Liñan¹², Carmen Mateo-Pascual¹³, Mª Mercedes Molina del Rio¹⁴, Mercedes Retamal-Ortiz¹⁵, Aida Fatima Lopez-Laguna¹⁶, Ruth Molera-Valero¹⁷, Sara Alvar-Pariente¹⁸, Antonio Pascual¹⁹, Adolfo Arias-Senso²⁰, Nuria Perez-Gutierrez²¹, Soledad Garcia-Frias²², David Bouza-Alvarez²³, Susana Sostres²⁴, Daniel Suarez-Hernandez²⁵, Ana Zamora-Casal²⁶, Cristina Garcia-Ramirez²⁷ and Enrique González-Dávila²⁸, and OsteoSER Project Collaborative Group, ¹Hospital Universitari de Bellvitge, 08907 L'Hospitalet, Catalonia, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Sociedad Española de Reumatología, Madrid, Madrid, Spain, ⁴Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Hospital Universitario de la Princesa, Madrid, Spain, ⁶Hospital Universitari de Vic (Consorci Hospitalari de Vic), Barcelona, Spain, ⁷Hospital Universitario Fundacion Alcorcon, Madrid, Spain, ⁸Hospital Universitario Central de Asturias, Oviedo, Spain, ⁹Hospital Universitario La Paz, Madrid, Spain, ¹⁰Conselleria de Sanitat/Hospital de la Vega Baja, Orihuela, Comunidad Valenciana, Spain, ¹¹Clínica Sanz y Correa, A Coruña, Spain, ¹²Hospital Don Benito-Villanueva, Don Benito, Spain, ¹³Centro de Salud Fuencarral, distrito Fuencarral-El Pardo, Madrid, Spain, ¹⁴Centro de Atención Primaria Viladecans Montbaig, Sant Climent de Llobregat, Spain, ¹⁵Centro de Salud Don Benito Oeste, Don Benito, Spain, ¹⁶Centro de Salud El Molar, El Molar, Spain, ¹⁷Centro de Salud Orihuela 1-El Rabaloche, Orihuela, Spain, ¹⁸Centro de Salud Malpica, Malpica, Spain, ¹⁹Centro de salud Ronda-Norte y Ronda-Sur Santa Bárbara, Ronda, Spain, ²⁰Centro de Salud de Santa Amalia, Santa Amalia, Spain, ²¹Centro de Atención Primaria Ramona Via i Pros, El Prat de Llobregat, Spain, ²²Centro de Salud de Cortes de la Frontera, Cortes de la Frontera, Spain, ²³Centro de Salud Elviña Mesoiro, A Coruña, Spain, ²⁴Centro de Atención Primaria Cap 17 de setembre, El Prat de Llobregat, Spain, ²⁵Centro de Salud de Benejuzar, Benezujar, Spain, ²⁶Centro de Salud Os Mallos, A Coruña, Spain, ²⁷Centro de Salud Ronda-Sur Santa Bárbara, Ronda, Spain, ²⁸Departamento de Matemáticas, Estadística e Investigación Operativa, Universidad La Laguna, San Cristobal de La Laguna, Spain
Background/Purpose: The bone mineral density (BMD) reference data for the Spanish population comes from the study Multicentre Research Project on Osteoporosis (MPRO), concluded in 1989.Our…
Abstract Number: 0159 • ACR Convergence 2024
Prevalence and Potential Factors Associated with Polypharmacy in Individuals with Systemic Lupus Erythematosus
Jianing Yang¹, Jinoos Yazdany², S. Sam Lim³, Brad Pearce³ and Laura Plantinga⁴, ¹Highland Hospital, AHS, San Leandro, CA, ²UCSF, San Francisco, CA, ³Emory University, Atlanta, GA, ⁴University of California, San Francisco, San Francisco, CA
Background/Purpose: Polypharmacy is associated with an increased risk of adverse drug effects and medication nonadherence. However, the prevalence of polypharmacy and the medications and factors…
Abstract Number: 2415 • ACR Convergence 2024
Characterizing the Population with Suspected Lupus Nephritis in Care of a Community Rheumatology Network
Nehad Soloman¹, Jawad Bilal², Romy Cabacungan³, Scott Milligan⁴, Andrew Sharobeem⁵, John Tesser⁶ and Henry Leher⁷, ¹Arizona Arthritis & Rheumatology Associates, P.C., Glendale, AZ, ²University of Arizona, Tucson, AZ, ³Arizona Arthritis & Rheumatology Associates, P.C., Tucson, AZ, ⁴Trio Health, Louisville, CO, ⁵AARA, Peoria, AZ, ⁶Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁷Aurinia Pharma, Stowe, VT
Background/Purpose: Lupus nephritis (LN) has been estimated to develop in up to 40% of all patients with systemic lupus erythematosus (SLE), with higher rates in…
Abstract Number: 0475 • ACR Convergence 2023
Prevalence of Endometriosis and Polycystic Ovarian Syndrome in Patients with Rheumatic Diseases in the United States
Sabahat Usmani¹, Catherine Lavallee², Maria Antonelli³ and Cuoghi Edens⁴, ¹Weiss Memorial Hospital, Chicago, IL, ²Virginia Tech Carilion School of Medicine, Roanoke, VA, ³MetroHealth System, Cleveland, OH, ⁴University of Chicago, Chicago, IL
Background/Purpose: Endometriosis (ENDO) and Polycystic Ovarian Syndrome (PCOS) are underdiagnosed, often debilitating conditions with unknown etiologies that, like rheumatic diseases, affect reproductive-aged women. Recent studies…
Abstract Number: 0543 • ACR Convergence 2023
Sensitivity of the 2019 European Alliance of Associations for Rheumatology /American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Population-based Cohort; A Study Set in Norway 2000-2015
Hilde Haukeland¹, Sigrid Reppe Moe¹, Cathrine Brunborg², Antonela Botea³, Nenad Damjanic⁴, Gro Wivestad⁵, Heidi Øvreås⁶, Thea Bøe⁷, Torhild Garen¹, Anniken Orre⁸, Helga Sanner⁹, Øyvind Molberg¹⁰ and Karoline Lerang⁹, ¹Oslo University Hospital, Department of Rheumatology, Oslo, Norway, ²Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, ³Betanien Hospital, Department of Rheumatology, Skien, Norway, ⁴Ostfold Hospital Trust, Department of Rheumatology,, Grålum, Norway, ⁵Hospital of Southern Norway Trust, Division of Rheumatology, Department of Medicine, Kristiansand, Norway, ⁶Lillehammer Hospital for Rheumatic Diseases, Department of Rheumatology, Lillehammer, Norway, ⁷Vestfold Hospital Trust, Department of Internal Medicine, Tønsberg, Norway, ⁸Vestre Viken Hospital Trust, Department of Rheumatology, Drammen, Norway, ⁹Oslo University Hospital, Department of Rheumatology, Nydalen, Norway, ¹⁰University of Oslo, Institute of Clinical Medicine, Oslo, Norway
Background/Purpose: To diagnose Systemic Lupus Erythematosus (SLE), one must understand the phenotype specter and interpret clinical, serological, radiological, and histopathological data, as well as exclude…
Abstract Number: 0751 • ACR Convergence 2023
Recombinant Zoster Vaccination Among U.S. Veterans Receiving Immunosuppressive Medications 2017-2023
Sharon Abada¹, Jing Li¹, Gary Tarasovsky², Cherish Wilson³, Jinoos Yazdany¹, Mary Whooley¹ and Gabriela Schmajuk³, ¹University of California San Francisco, San Francisco, CA, ²San Francisco VA, San Francisco, CA, ³UCSF / SFVA, San Francisco, CA
Background/Purpose: Patients receiving immunosuppressive therapies are known to have a higher risk of herpes zoster and subsequent complications compared to the general population. The recombinant…
Abstract Number: 0977 • ACR Convergence 2023
Prevalence of Arthritis in the United States: National Estimates from a Population-based Study
Sumanth Chandrupatla¹, Kranti Rumalla² and Jasvinder Singh¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Northwestern School of Medicine, Chicago, IL
Background/Purpose: Arthritis is the number 1 cause of disability among U.S. adults and reported to cost > $300 billion in direct and indirect costs in…
Abstract Number: 1166 • ACR Convergence 2023
Patients with COVID-19 and Polymyositis Inpatient Outcomes and Hospital Cost: Nationwide Inpatient Sample 2020
Emily He¹ and Vaneet Sandhu², ¹Loma Linda University Health, Loma Linda, CA, ²Loma Linda University, Loma Linda, CA
Background/Purpose: During the COVID-19 pandemic, there were growing concerns regarding the impact of SARS-CoV-2 on not only patients with rheumatic diseases but also the national…
Abstract Number: 1821 • ACR Convergence 2023
The “Weekend Effect” and Rheumatological Association in Patients with Diffuse Alveolar Haemorrhage
Shobhit Piplani¹, Shreya Gulati², Vladimir Jelic¹, Asad Ahmed³, Sung Mi Yoon¹, Donclair Brown¹, Miroslav Radulovic¹ and Beverly Johnson⁴, ¹Jacobi Medical Center/North Central Bronx, Albert Einstein College of Medicine, NYC Health and Hospitals, Bronx, NY, ²Jawahar lal Nehru Medical College, New York, NY, ³SUNY Downstate, Brooklyn, NY, ⁴Albert Einstein College of Medicine, Jacobi/NCB, New York, NY
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a life-threatening pulmonary complication commonly associated with autoimmune disorders. Limited treatment options are available for DAH, and time to…
Abstract Number: 1918 • ACR Convergence 2023
Nationwide Analysis of Predictors of Sarcoid Inpatient Mortality
Michael Manansala¹, Faria Sami², Shilpa Arora³ and Augustine Manadan¹, ¹Rush University Medical Center, Chicago, IL, ²John H. Stroger Jr. Hospital of Cook County, Chicago, IL, ³Cook County Hospital, Chicago, IL
Background/Purpose: Sarcoidosis is multisystem autoimmune disease characterized by noncaseating granulomas which can result in significant morbidity and mortality. This study aims to identify variables associated…
Abstract Number: 1947 • ACR Convergence 2023
National Incidence, Prevalence & Mortality in Idiopathic Inflammatory Myopathies & Associated Interstitial Lung Disease in England
Jennifer Hannah¹, Fiona Pearce², Myron Odingo², Megan Rutter², Jeanette Aston³, Jennifer Lai³, Matthew Grainge², Sean Mcphail³, Peter Lanyon², Mary Bythell³, James Galloway⁴ and Patrick Gordon⁵, ¹King's College London, London, United Kingdom, ²University of Nottingham, Nottingham, United Kingdom, ³National Disease Registration Service, Leeds, United Kingdom, ⁴King's College London, London, United Kingdom, ⁵NHS, London, United Kingdom
Background/Purpose: Ethnicity, sex, age & socioeconomic deprivation can all lead to health inequity. Impact of these factors in epidemiology of Idiopathic Inflammatory Myopathies (IIM) has…
Abstract Number: 1953 • ACR Convergence 2023
Mortality Trends in Polymyositis and Dermatomyositis in Mexico: A General Population-based Study from 2000 to 2019
CLAUDIA MENDOZA PINTO¹, Pamela Munguía-Realpozo¹, Ivet Etchegaray-Morales², Mario García-Carrasco², Paulina Cortés-Hernández¹, Roberto Arreguín-Reyes¹, Jorge Ayón-Aguilar¹ and Gabriel Rodríguez-Castillo², ¹Instituto Mexicano del Seguro Socia, Puebla, Mexico, ²Medicine School, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
Background/Purpose: Patients with polymyositis and dermatomyositis (PM/DM) present multiple complications that may lead to increased mortality rates and data on PM/DM mortality in Mexico is…
Abstract Number: 2406 • ACR Convergence 2023
Risk of Large Vessel Complications in Patients with Giant Cell Arteritis, a Population-based Study
Mohanad Elfishawi¹, Mahmut Kaymakci¹, Sara Achenbach², Cynthia Crowson¹, Tanaz Kermani³, Cornelia M. Weyand⁴, Matthew Koster¹ and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, Rochester, MN, ³University of California Los Angeles, Los Angeles, CA, ⁴Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: Large vessel (LV) complications are known to occur in patients with giant cell arteritis (GCA). The magnitude of risk compared to the general population…
Abstract Number: 0108 • ACR Convergence 2023
Decoding Antiphospholipid Syndrome Laboratory Test Outcomes in a Large Multicenter Electronic Health Record Database
Emily Balczewski, Wenying Liang, Amala Ambati, Yu Zuo, Karandeep Singh and Jason Knight, University of Michigan, Ann Arbor, MI
Background/Purpose: Electronic health record (EHR) data provide an inexpensive, information-rich tool to study rare diseases like antiphospholipid syndrome (APS). Many such studies rely on structured…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].